Evidence map›Paper›PMID 42199639›Full record

ArticleTherapeutics and clinical risk management2026

The ESINEA Study: A Novel Screening Tool for Identifying Patient Safety Incidents and Adverse Events in Hospitalized Patients-An Index-Date Cohort Evaluation.

Fiorela C Dueñas Lopez, Alba Fernández-Arroyo García, M Angélica Rivera Núñez, Beatriz Díaz-Pollán, Carmen Sobrino Jiménez, Concepción Murillo Gayo, Covadonga Mendieta Azcona, Cristina Jiménez Núñez, Gema Yagüe de Antonio, Inés Narrillos Martín and 23 more

Abstract read
In one paragraph

Article in Therapeutics and clinical risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Fiorela C Dueñas LopezClinical Pharmacology Department, General Hospital, La Paz University Hospital-Idipaz, School of Medicine, Autonomous University of Madrid, Madrid, Spain.ORCID 0009-0006-0314-3957
Alba Fernández-Arroyo GarcíaHemato-Oncology Department, Children's Hospital, La Paz University Hospital, Madrid, Spain.
M Angélica Rivera NúñezPatient Safety Unit, General Hospital, La Paz University Hospital, Madrid, Spain.
Beatriz Díaz-PollánInfectious Diseases Unit, Internal Medicine Department, General Hospital, La Paz University Hospital, Madrid, Spain.
Carmen Sobrino JiménezHospital Pharmacy Department, General Hospital, La Paz University Hospital, Madrid, Spain.
Concepción Murillo GayoGeriatrics Department, General Hospital, La Paz University Hospital, Madrid, Spain.
Covadonga Mendieta AzconaAngiology and Vascular Surgery Department, General Hospital, La Paz University Hospital, Madrid, Spain.
Cristina Jiménez NúñezHospital Pharmacy Department, General Hospital, La Paz University Hospital, Madrid, Spain.
Gema Yagüe de AntonioFunctional Area of Quality, General Hospital, La Paz University Hospital, Madrid, Spain.
Inés Narrillos MartínGeneral Surgery Department, General Hospital, La Paz University Hospital, Madrid, Spain.ORCID 0009-0009-7068-0375
Javier Guijarro EguinoaClinical Pharmacology Department, General Hospital, La Paz University Hospital-Idipaz, School of Medicine, Autonomous University of Madrid, Madrid, Spain.
José Jonay Ojeda FeoOffice of Sustainable Development and Agenda 2030, General Hospital, La Paz University Hospital, Madrid, Spain.
María Asunción González de la ViudaLegal Department, General Hospital, La Paz University Hospital, Madrid, Spain.
María Del Carmen Bautista ReinaSan José Pavilion, Cantoblanco Hospital, La Paz University Hospital, Madrid, Spain.
María Fernández Velilla PeñaRadiodiagnosis Department, General Hospital, La Paz University Hospital, Madrid, Spain.
María Jiménez-GonzalezUCICEC (Analysis and Statistics Platform), General Hospital, La Paz University Hospital, Madrid, Spain.
Marta Duque AlcortaClinical Analysis Department, General Hospital, La Paz University Hospital, Madrid, Spain.
Miguel Álvarez-MonteroClinical Pharmacology Department, General Hospital, La Paz University Hospital-Idipaz, School of Medicine, Autonomous University of Madrid, Madrid, Spain.ORCID 0009-0002-4896-1815
Miguel González MuñozImmunology Department, General Hospital, La Paz University Hospital, Madrid, Spain.
Miguel Lorente RomeoInformation Technology Department, General Hospital, La Paz University Hospital, Madrid, Spain.
Nelson M Buitrago SánchezRadiodiagnosis Department, Children's Hospital, La Paz University Hospital, Madrid, Spain.ORCID 0000-0001-5265-723X
Olga RogozinaClinical Pharmacology Department, General Hospital, La Paz University Hospital-Idipaz, School of Medicine, Autonomous University of Madrid, Madrid, Spain.
Paloma López OrtegoNeonatology Department, Children's Hospital, La Paz University Hospital, Madrid, Spain.
Ramón Pardo PurasClinical Pharmacology Department, General Hospital, La Paz University Hospital-Idipaz, School of Medicine, Autonomous University of Madrid, Madrid, Spain.ORCID 0009-0007-1218-0394
Rosario Maria Torres Santos OlmoDigital Strategy, and Innovation, General Hospital, La Paz University Hospital, Madrid, Spain.
Silvia Iniesta PérezGynecology Department, Maternity Hospital, La Paz University Hospital, Madrid, Spain.ORCID 0000-0002-6581-8642
Susana Chajma IzquierdoRehabilitation Department, Carlos III Hospital, La Paz University Hospital, Madrid, Spain.
Susana Martín LópezClinical Pharmacology Department, General Hospital, La Paz University Hospital-Idipaz, School of Medicine, Autonomous University of Madrid, Madrid, Spain.
Teresa Del RosalInfectious Diseases Unit, Pediatrics Department, Children's Hospital, La Paz University Hospital, Madrid, Spain.ORCID 0000-0002-8756-7020
Paola Parra RamírezEndocrinology and Nutrition Department, General Hospital, La Paz University Hospital, Madrid, Spain.ORCID 0000-0002-0310-7095
Yuri Fabiola Villán VillánPreventive Medicine Department, General Hospital, La Paz University Hospital, Madrid, Spain.
Alberto Martín VegaCSUR Coordination, General Hospital, La Paz University Hospital, Madrid, Spain.
Elena RamírezClinical Pharmacology Department, General Hospital, La Paz University Hospital-Idipaz, School of Medicine, Autonomous University of Madrid, Madrid, Spain.ORCID 0000-0002-4052-8876

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study, ESINEA, investigated the period prevalence and characteristics of Patient Safety Incidents (PSIs) at La Paz University Hospital. PSIs were operationally defined as healthcare-related events with the potential to cause patient harm, including near misses, incidents, and adverse events (AEs) resulting in actual injury. Recognizing the critical importance of patient safety and the limitations of existing AE detection methods, the study aimed to improve identification and understanding of these incidents. Methodology: An index-date inpatient cohort study was conducted, including all patients hospitalized at La Paz University Hospital on April 23 Results: The population showed a high rate of urgent admissions (79%) and a predominance of older patients (75-85 years old, 19.5%). Phase I identified at least one positive screening trigger in 58% of patients. Following expert adjudication, the period prevalence of PSI was 47.9% (95%CI: 45.16-50.72), and AEs were confirmed in 27% (95% CI: 24.17-30.06). Phase II confirmed that PSI accounted for 92.35% of the positive screening. The most frequent incidents occurred during "patient care and follow-up" (29.95%), followed by "Healthcare-Associated Infections" (17.21%). Vulnerability to PSI was significantly higher among older patients, those with longer hospital stays, and those with higher comorbidity burdens. Although 34.17% of PSIs were deemed preventable, slightly lower than the expected 40%;the analysis identified 88 distinct types of improvement actions to enhance patient safety. Conclusion: The ESINEA study identified a high period prevalence of AEs (27%) in hospitalized patients, which is higher than the estimated 10% prevalence often cited. Although direct comparisons require caution due to differences in detection sensitivity and study design, these findings underscore the need for enhanced care coordination, infection prevention, and stricter protocol adherence, particularly among vulnerable populations.

Indexed as

adverse eventsepidemiologyhospital settingimprovement actionsincidentspatient safetypatient safety culturepatient safety incidentspreventabilitysurveillance

Identifiers

PMID42199639
PMCPMC13200203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.